Chemotherapy Research Today is a free monthly online journal that collates and summarizes the latest research about Chemotherapy, including details on cancer treatment, side effects, drugs.

Volume 2 (2005), Issue 4 (April)

1. Continuous remission of newly diagnosed and relapsed central nervous system atypical teratoid/rhabdoid tumor.
   J Neurooncol, 72(1): 77-84. [Abstract] [Full-text]
2. Human interferon beta, nimustine hydrochloride, and radiation therapy in the treatment of newly diagnosed malignant astrocytomas.
   J Neurooncol, 72(1): 57-62. [Abstract] [Full-text]
3. Cell specific effects of polyunsaturated fatty acids on 5-aminolevulinic acid based photosensitization.
   Photochem Photobiol Sci, 4(4): 383-9. [Abstract] [Full-text]
4. Transgene delivery and gelonin cytotoxicity enhanced by photochemical internalization in fibroblast-like synoviocytes (FLS) from rheumatoid arthritis patients.
   Photochem Photobiol Sci, 4(4): 341-7. [Abstract] [Full-text]
5. Sensitization for anticancer drug-induced apoptosis by betulinic Acid.
   Neoplasia, 7(2): 162-70. [Abstract] [Full-text]
6. Early response to induction is predictive of survival in childhood Philadelphia chromosome positive acute lymphoblastic leukaemia: results of the Medical Research Council ALL 97 trial.
   Br J Haematol, 129(1): 35-44. [Abstract] [Full-text]
7. Self treatment with one of three self selected, ultramolecular homeopathic medicines for the prevention of upper respiratory tract infections in children. A double-blind randomized placebo controlled trial.
   Br J Clin Pharmacol, 59(4): 447-55. [Abstract] [Full-text]
8. Nucleosomes in pancreatic cancer patients during radiochemotherapy.
   Tumour Biol, 26(1): 44-9. [Abstract] [Full-text]
9. Impact of TCR status and genotype on outcome in adult T-cell acute lymphoblastic leukemia: a LALA-94 study.
   Blood, 105(8): 3072-8. [Abstract] [Full-text]
10. Combined thalidomide and cyclophosphamide treatment for refractory or relapsed multiple myeloma patients: a prospective phase II study.
    Ann Hematol, 84(5): 311-6. [Abstract] [Full-text]
11. Bone regeneration in the rat mandible with bone morphogenetic protein-2: a comparison of two carriers.
    Otolaryngol Head Neck Surg, 132(4): 592-7. [Abstract] [Full-text]
12. Insights from the sharp end of intravenous medication errors: implications for infusion pump technology.
    Qual Saf Health Care, 14(2): 80-6. [Abstract] [Full-text]
13. Use of volume expansion during delivery room resuscitation in near-term and term infants.
    Pediatrics, 115(4): 950-5. [Abstract] [Full-text]
14. Enhancement of the therapeutic efficacy of taxol by the mitogen-activated protein kinase kinase inhibitor CI-1040 in nude mice bearing human heterotransplants.
    Cancer Res, 65(7): 2854-60. [Abstract] [Full-text]
15. Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts.
    Cancer Res, 65(7): 2825-31. [Abstract] [Full-text]
16. Identification of the genes involved in enhanced fenretinide-induced apoptosis by parthenolide in human hepatoma cells.
    Cancer Res, 65(7): 2804-14. [Abstract] [Full-text]
17. A fuzzy logic based closed-loop control system for blood glucose level regulation in diabetics.
    J Med Eng Technol, 29(2): 64-9. [Abstract] [Full-text]
18. Coronary aneurysm after implantation of a paclitaxel-eluting stent.
    Scand Cardiovasc J, 38(6): 349-52. [Abstract] [Full-text]
19. Effects of conjugated equine estrogens or raloxifene on lipid profile, coagulation and fibrinolysis factors in postmenopausal women.
    Climacteric, 8(1): 63-70. [Abstract] [Full-text]
20. Relevance of the results of the Women's Health Initiative on the prescription of hormone therapy in Spain.
    Climacteric, 8(1): 36-48. [Abstract] [Full-text]
21. Women's perceptions of hormone replacement therapy: risks and benefits (1980-2002). A literature review.
    Climacteric, 8(1): 24-35. [Abstract] [Full-text]
22. Effects of low-dose hormone therapy on menopausal symptoms, bone mineral density, endometrium, and the cardiovascular system: a review of randomized clinical trials.
    Climacteric, 8(1): 13-23. [Abstract] [Full-text]
23. KEEPS: The Kronos Early Estrogen Prevention Study.
    Climacteric, 8(1): 3-12. [Abstract] [Full-text]
24. Mandibular defect repair by TGF-beta and IGF-1 released from a biodegradable osteoconductive hydrogel.
    J Craniomaxillofac Surg, 33(2): 79-84. [Abstract] [Full-text]
25. Directed antigen presentation using polymeric microparticulate carriers degradable at lysosomal pH for controlled immune responses.
    Mol Pharm, 2(1): 83-91. [Abstract] [Full-text]
26. Superior cell delivery features of poly(ethylene glycol) incorporated alginate, chitosan, and poly-L-lysine microcapsules.
    Mol Pharm, 2(1): 29-36. [Abstract] [Full-text]
27. Primary mediastinal B-cell lymphoma with sclerosis: report of 11 cases treated with intensified-CHOP plus radiotherapy.
    Am J Hematol, 78(4): 312-3. [Abstract] [Full-text]
28. The rate of serious bacterial infections among HIV-infected children with immune reconstitution who have discontinued opportunistic infection prophylaxis.
    Pediatrics, 115(4): e488-94. [Abstract] [Full-text]
29. Antidiarrheal effects of L-histidine-supplemented rice-based oral rehydration solution in the treatment of male adults with severe cholera in Bangladesh: a double-blind, randomized trial.
    J Infect Dis, 191(9): 1507-14. [Abstract] [Full-text]
30. Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1.
    J Infect Dis, 191(9): 1410-8. [Abstract] [Full-text]
31. Impact of 3-tier formularies on drug treatment of attention-deficit/hyperactivity disorder in children.
    Arch Gen Psychiatry, 62(4): 435-41. [Abstract] [Full-text]
32. Endogenous and exogenous hormone exposure and risk of cognitive impairment in Swedish twins: a preliminary study.
    Psychoneuroendocrinology, 30(6): 558-67. [Abstract] [Full-text]
33. Estrogen replacement therapy and retinal vascular caliber.
    Ophthalmology, 112(4): 553-8. [Abstract] [Full-text]
34. Photodynamic therapy in young patients with choroidal neovascularization following traumatic choroidal rupture.
    Am J Ophthalmol, 139(4): 726-8. [Abstract] [Full-text]
35. Persistently high IgA serum levels are a marker of immunological or virological failure of combined antiretroviral therapy in children with perinatal HIV-1 infection.
    Clin Exp Immunol, 140(2): 320-4. [Abstract] [Full-text]
36. Antiretroviral treatment in resource-poor settings: public health research priorities.
    Trop Med Int Health, 10(4): 295-9. [Abstract] [Full-text]
37. Conceptions of evidence, evidence-based medicine, evidence-based practice and their use in nursing: independent nurse prescribers' views.
    J Clin Nurs, 14(4): 411-7. [Abstract] [Full-text]
38. Drug molecules as probes for studying the compatibility between gels and mucous tissue with dielectric spectroscopy.
    J Pharm Sci, 94(5): 1090-100. [Abstract] [Full-text]
39. Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy.
    Hepatology, 41(4): 753-60. [Abstract] [Full-text]
40. Evolving role of myeloablative chemotherapy in the treatment of childhood brain tumours.
    Bone Marrow Transplant, 35: S31-4. [Abstract] [Full-text]
41. Phase I and pharmacokinetic study of docetaxel combined with melphalan and carboplatin, with autologous hematopoietic progenitor cell support, in patients with advanced refractory malignancies.
    Biol Blood Marrow Transplant, 11(4): 297-306. [Abstract] [Full-text]
42. 'Successful' chemo- and radiotherapy prior to radical cystectomy does not necessarily correlate with clinical course in small cell carcinoma of the bladder.
    Urol Int, 74(3): 286-8. [Abstract] [Full-text]
43. Menopausal hormone therapy after breast cancer: the Stockholm randomized trial.
    J Natl Cancer Inst, 97(7): 533-5. [Abstract] [Full-text]
44. Randomized study of maintenance vinorelbine in responders with advanced non-small-cell lung cancer.
    J Natl Cancer Inst, 97(7): 499-506. [Abstract] [Full-text]
45. Docetaxel for treatment of solid tumours: a systematic review of clinical data.
    Lancet Oncol, 6(4): 229-39. [Abstract] [Full-text]
46. Impact of an adherence clinic on behavioral outcomes and virologic response in treatment of HIV infection: a prospective, randomized, controlled pilot study.
    Clin Ther, 27(2): 199-209. [Abstract] [Full-text]
47. Hormone use for menopausal symptoms and risk of breast cancer. A Danish cohort study.
    Br J Cancer, 92(7): 1293-7. [Abstract] [Full-text]
48. Intensified concurrent chemoradiotherapy with 5-fluorouracil and irinotecan as neoadjuvant treatment in patients with locally advanced rectal cancer.
    Br J Cancer, 92(7): 1215-20. [Abstract] [Full-text]
49. Sequential treatment with irinotecan and doxifluridine: optimal dosing schedule in murine models and in a phase I study for metastatic colorectal cancer.
    Chemotherapy, 51(1): 32-9. [Abstract] [Full-text]
50. Modification of the Bu/Cy myeloablative regimen using daily parenteral busulfan: reduced toxicity without the need for pharmacokinetic monitoring.
    Bone Marrow Transplant, 35(8): 747-54. [Abstract] [Full-text]
51. A multidisciplinary treatment strategy that includes high-dose chemotherapy for metastatic retinoblastoma without CNS involvement.
    Bone Marrow Transplant, 35(8): 763-6. [Abstract] [Full-text]
52. Bleeding complications after contemporary pharmacoinvasive therapy for ST elevation myocardial infarction.
    J Thromb Thrombolysis, 18(3): 187-92. [Abstract] [Full-text]
53. Potential antagonism of tubulin-binding anticancer agents in combination therapies.
    Clin Cancer Res, 11(7): 2720-6. [Abstract] [Full-text]
54. A phase I clinical, pharmacologic, and biologic study of thrombopoietin and granulocyte colony-stimulating factor in children receiving ifosfamide, carboplatin, and etoposide chemotherapy for recurrent or refractory solid tumors: a Children's Oncology Group experience.
    Clin Cancer Res, 11(7): 2644-50. [Abstract] [Full-text]
55. Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling.
    Clin Cancer Res, 11(7): 2625-36. [Abstract] [Full-text]
56. Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin.
    Clin Cancer Res, 11(7): 2620-4. [Abstract] [Full-text]
57. Long-term results of a multicenter randomized, comparative trial of modified CHOP versus THP-COP versus THP-COPE regimens in elderly patients with non-Hodgkin's lymphoma.
    Int J Hematol, 81(3): 246-54. [Abstract] [Full-text]
58. Investigation of lectin-modified insulin liposomes as carriers for oral administration.
    Int J Pharm, 294(1): 247-59. [Abstract] [Full-text]
59. A critical evaluation of the relevant parameters for drug redispersion from adhesive mixtures during inhalation.
    Int J Pharm, 294(1): 173-84. [Abstract] [Full-text]
60. Cubic liquid crystalline glyceryl monooleate matrices for oral delivery of enzyme.
    Int J Pharm, 294(1): 161-71. [Abstract] [Full-text]
61. Alginate rafts and their characterisation.
    Int J Pharm, 294(1): 137-47. [Abstract] [Full-text]
62. Skin targeted DNA vaccine delivery using electroporation in rabbits. I: efficacy.
    Int J Pharm, 294(1): 53-63. [Abstract] [Full-text]
63. Biodegradable dextran-based microspheres for delivery of anticancer drug mitomycin C.
    Biomaterials, 26(26): 5375-85. [Abstract] [Full-text]
64. Unity from diversity: the evidential use of anecdotal reports of adverse drug reactions and interactions.
    J Eval Clin Pract, 11(2): 195-208. [Abstract] [Full-text]
65. Novel polyelectrolyte carboxymethyl konjac glucomannan-chitosan nanoparticles for drug delivery. I. Physicochemical characterization of the carboxymethyl konjac glucomannan-chitosan nanoparticles.
    Biopolymers, 78(1): 1-8. [Abstract] [Full-text]
66. Oral estradiol decreases plasma homocysteine, vitamin B6, and albumin in postmenopausal women but does not change the whole-body homocysteine remethylation and transmethylation flux.
    J Clin Endocrinol Metab, 90(4): 2218-24. [Abstract] [Full-text]
67. Short-term effects of growth hormone (GH) treatment or deprivation on cardiovascular risk parameters and intima-media thickness at carotid arteries in patients with severe GH deficiency.
    J Clin Endocrinol Metab, 90(4): 2056-62. [Abstract] [Full-text]
68. A phase I, dose-finding study of irinotecan (CPT-11) short i.v. infusion combined with fixed dose of 5-fluorouracil (5-FU) protracted i.v. infusion in adult patients with advanced solid tumours.
    Cancer Chemother Pharmacol, 55(5): 453-60. [Abstract] [Full-text]
69. Reirradiation alternating with docetaxel and cisplatin in inoperable recurrence of head-and-neck cancer: a prospective phase I/II trial.
    Int J Radiat Oncol Biol Phys, 61(5): 1423-31. [Abstract] [Full-text]
70. Phase I trial of Orzel (UFT plus leucovorin), cisplatin, and radiotherapy in the treatment of potentially resectable esophageal cancer.
    Int J Radiat Oncol Biol Phys, 61(5): 1364-70. [Abstract] [Full-text]
71. Seizure suppression and lack of adenosine A1 receptor desensitization after focal long-term delivery of adenosine by encapsulated myoblasts.
    Exp Neurol, 193(1): 53-64. [Abstract] [Full-text]
72. Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists.
    J Clin Oncol, 23(11): 2477-92. [Abstract] [Full-text]
73. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer.
    J Clin Oncol, 23(11): 2544-55. [Abstract] [Full-text]
74. Safety and feasibility of a lower dose intravenous TPA therapy for ischemic stroke beyond the first three hours.
    Cerebrovasc Dis, 19(4): 260-6. [Abstract] [Full-text]
75. A case-control analysis of intra-arterial urokinase thrombolysis in acute cardioembolic stroke.
    Cerebrovasc Dis, 19(4): 225-8. [Abstract] [Full-text]
76. Significant induction of cyclophosphamide and thiotepa metabolism by phenytoin.
    Cancer Chemother Pharmacol, 55(5): 507-10. [Abstract] [Full-text]
77. Phase I trial of weekly docetaxel with a 4-weekly cisplatin administration in patients with advanced gastric carcinoma.
    Cancer Chemother Pharmacol, 55(5): 466-70. [Abstract] [Full-text]
78. Management of pelvic lymphocysts by ultrasound-guided aspiration and minocycline sclerotherapy.
    Gynecol Obstet Invest, 59(3): 130-3. [Abstract] [Full-text]
79. Report of an early stopped randomized trial comparing cisplatin vs. cisplatin/ifosfamide/ 5-fluorouracil in recurrent cervical cancer.
    Gynecol Obstet Invest, 59(3): 126-9. [Abstract] [Full-text]
80. Large-cell neuroendocrine carcinoma of the lung: a clinicopathologic study of eighteen cases and the efficacy of adjuvant treatment with octreotide.
    J Thorac Cardiovasc Surg, 129(4): 819-24. [Abstract] [Full-text]
81. Three emerging new drugs for NSCLC: pemetrexed, bortezomib, and cetuximab.
    Oncologist, 10(4): 282-91. [Abstract] [Full-text]
82. Critical evaluation of current treatments in metastatic colorectal cancer.
    Oncologist, 10(4): 250-61. [Abstract] [Full-text]
83. Pathological and clinical response of a primary chemotherapy regimen combining vinorelbine, epirubicin, and paclitaxel as neoadjuvant treatment in patients with operable breast cancer.
    Oncologist, 10(4): 242-9. [Abstract] [Full-text]
84. Transforming growth factor-beta3 induces pleurodesis in rabbits and collagen production of human mesothelial cells.
    Chest, 127(4): 1335-40. [Abstract] [Full-text]
85. The mathematical modelling of adjuvant chemotherapy scheduling: incorporating the effects of protocol rest phases and pharmacokinetics.
    Bull Math Biol, 67(3): 563-611. [Abstract] [Full-text]
86. Administration of estradiol and progesterone modulate the activities of antioxidant enzyme and aminotransferases in naturally menopausal rats.
    Exp Gerontol, 40(4): 295-302. [Abstract] [Full-text]
87. Tight junctions, from tight intercellular seals to sophisticated protein complexes involved in drug delivery, pathogens interaction and cell proliferation.
    Adv Drug Deliv Rev, 57(6): 811-4. [Abstract] [Full-text]
88. Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project.
    Am J Surg, 189(4): 395-404. [Abstract] [Full-text]
89. Starch/Carbopol spray-dried mixtures as excipients for oral sustained drug delivery.
    J Control Release, 103(3): 635-41. [Abstract] [Full-text]
90. Role of polyanhydrides as localized drug carriers.
    J Control Release, 103(3): 541-63. [Abstract] [Full-text]
91. Photochemical repair of Achilles tendon rupture in a rat model.
    J Surg Res, 124(2): 274-9. [Abstract] [Full-text]
92. Antibiotic prophylaxis with azithromycin or penicillin for childhood-onset neuropsychiatric disorders.
    Biol Psychiatry, 57(7): 788-92. [Abstract] [Full-text]
93. Vascular consequences of menopause and hormone therapy: importance of timing of treatment and type of estrogen.
    Cardiovasc Res, 66(2): 295-306. [Abstract] [Full-text]
94. Factors influencing women's decisions to self-treat vaginal symptoms.
    J Am Acad Nurse Pract, 17(4): 156-62. [Abstract] [Full-text]
95. Polypharmacy in the elderly: a literature review.
    J Am Acad Nurse Pract, 17(4): 123-32. [Abstract] [Full-text]
96. Persistent rectal prolapse in children: sclerotherapy and surgical management.
    Pediatr Surg Int, 21(4): 270-3. [Abstract] [Full-text]
97. The mGluR5 antagonist MPEP decreases operant ethanol self-administration during maintenance and after repeated alcohol deprivations in alcohol-preferring (P) rats.
    Psychopharmacology (Berl), 179(1): 262-70. [Abstract] [Full-text]
98. Metabotropic glutamate 5 receptor blockade may attenuate cocaine self-administration by decreasing brain reward function in rats.
    Psychopharmacology (Berl), 179(1): 247-54. [Abstract] [Full-text]
99. Effects of estrogen replacement therapy on bone and glucose metabolism in a male with congenital aromatase deficiency.
    Horm Metab Res, 37(3): 178-83. [Abstract] [Full-text]
100. A prescribing cascade involving cholinesterase inhibitors and anticholinergic drugs.
     Arch Intern Med, 165(7): 808-13. [Abstract] [Full-text]
101. Guided prescription of psychotropic medications for geriatric inpatients.
     Arch Intern Med, 165(7): 802-7. [Abstract] [Full-text]
102. Safety and efficacy of intravitreal injection of ranibizumab in combination with verteporfin PDT on experimental choroidal neovascularization in the monkey.
     Arch Ophthalmol, 123(4): 509-16. [Abstract] [Full-text]
103. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial.
     Arch Ophthalmol, 123(4): 448-57. [Abstract] [Full-text]
104. Manufacturing techniques of biodegradable implants intended for intraocular application.
     Drug Deliv, 12(2): 109-16. [Abstract] [Full-text]
105. Systematic delivery of chloroquine and promethazine using pH-sensitive polymers.
     Drug Deliv, 12(2): 103-7. [Abstract] [Full-text]
106. Liposomes as alternative vehicles for sun filter formulations.
     Drug Deliv, 12(2): 83-8. [Abstract] [Full-text]
107. Sorbitan monopalmitate-based proniosomes for transdermal delivery of chlorpheniramine maleate.
     Drug Deliv, 12(2): 75-82. [Abstract] [Full-text]
108. Amplification of antibody responses to antigen using small multilamellar vesicles for delivery system.
     Drug Deliv, 12(2): 69-74. [Abstract] [Full-text]
109. Macrophage depletion induced by clodronate-loaded erythrocytes.
     J Drug Target, 13(2): 99-111. [Abstract] [Full-text]
110. Hormone replacement therapy and arterial blood pressure in postmenopausal women with hypertension.
     Blood Press, 14(1): 38-44. [Abstract] [Full-text]
111. Hormone replacement use, arterial distensibility, cardiac structure and circadian blood pressure profile in menopausal women.
     Blood Press, 14(1): 12-20. [Abstract] [Full-text]
112. Interdisciplinary working between community pharmacists and community nurses: the views of community pharmacists.
     J Interprof Care, 19(2): 164-70. [Abstract] [Full-text]
113. Hormone therapy and cardiovascular disease--still much to be learnt.
     Gynecol Endocrinol, 20(2): 116-20. [Abstract] [Full-text]
114. Different effects of tibolone and continuous combined estrogen plus progestogen hormone therapy on sex hormone binding globulin and free testosterone levels--an association with mammographic density.
     Gynecol Endocrinol, 20(2): 110-5. [Abstract] [Full-text]
115. Psychological effects of tibolone and sequential estrogen-progestogen therapy in perimenopausal women.
     Gynecol Endocrinol, 20(2): 64-7. [Abstract] [Full-text]
116. Treatment of acute lymphocytic leukemia using zinc adjuvant with chemotherapy and radiation--a case history and hypothesis.
     Med Hypotheses, 64(6): 1124-6. [Abstract] [Full-text]
117. Selected laser-based therapies in otolaryngology.
     Otolaryngol Clin North Am, 38(2): 241-54. [Abstract] [Full-text]
118. Placental site trophoblastic tumor presenting as subaponeurotic metastasis.
     Int J Gynecol Cancer, 15(2): 385-8. [Abstract] [Full-text]
119. Microsatellite instability is not related to response to cisplatin-based chemotherapy in cervical cancer.
     Int J Gynecol Cancer, 15(2): 308-11. [Abstract] [Full-text]
120. Predictive value of serum interleukin-8 levels in ovarian cancer patients treated with paclitaxel-containing regimens.
     Int J Gynecol Cancer, 15(2): 240-5. [Abstract] [Full-text]
121. A randomized prospective study of comparison of reservoir ports versus conventional vascular access in advanced-stage ovarian carcinoma cases treated with chemotherapy.
     Int J Gynecol Cancer, 15(2): 228-32. [Abstract] [Full-text]
122. Carboplatin hypersensitivity induced by low-dose paclitaxel/carboplatin in multiple platinum-treated patients with recurrent ovarian cancer.
     Int J Gynecol Cancer, 15(2): 224-7. [Abstract] [Full-text]
123. Neoadjuvant chemotherapy in advanced ovarian cancer: a case-control study.
     Int J Gynecol Cancer, 15(2): 217-23. [Abstract] [Full-text]
124. AngioJet rheolytic thrombectomy versus local intrapulmonary thrombolysis in massive pulmonary embolism: a retrospective data analysis.
     J Endovasc Ther, 12(2): 206-14. [Abstract] [Full-text]
125. Proteomic analysis of serum cytokine levels in response to highly active antiretroviral therapy (HAART).
     J Proteome Res, 4(2): 227-31. [Abstract] [Full-text]
126. Influence of estrogen therapy at conventional and high doses on the degree of mineralization of iliac bone tissue: a quantitative microradiographic analysis in postmenopausal women.
     Bone, 36(3): 562-7. [Abstract] [Full-text]
127. The effect of sub-lethal ALA-PDT on the cytoskeleton and adhesion of cultured human cancer cells.
     Biochim Biophys Acta, 1722(1): 43-50. [Abstract] [Full-text]
128. Merocyanine 540-sensitized photokilling of leukemia cells: role of post-irradiation chain peroxidation of plasma membrane lipids as revealed by nitric oxide protection.
     Biochim Biophys Acta, 1722(1): 51-9. [Abstract] [Full-text]
129. Lymph node metastasis in epithelial malignancies of the appendix with peritoneal dissemination does not reduce survival in patients treated by cytoreductive surgery and perioperative intraperitoneal chemotherapy.
     Ann Surg Oncol, 12(1): 72-80. [Abstract] [Full-text]
130. Parthenolide and sulindac cooperate to mediate growth suppression and inhibit the nuclear factor-kappa B pathway in pancreatic carcinoma cells.
     Mol Cancer Ther, 4(4): 587-94. [Abstract] [Full-text]
131. RNA expression profiling of normal and tumor cells following photodynamic therapy with 5-aminolevulinic acid-induced protoporphyrin IX in vitro.
     Mol Cancer Ther, 4(4): 516-28. [Abstract] [Full-text]
132. Relationship of incorrect dosing of fibrinolytic therapy and clinical outcomes.
     JAMA, 293(14): 1746-50. [Abstract] [Full-text]
133. Intravenous fluid-associated morbidity in postoperative patients.
     Ann R Coll Surg Engl, 87(2): 126-30. [Abstract] [Full-text]
134. Dual specificity protein phosphatases: therapeutic targets for cancer and Alzheimer's disease.
     Annu Rev Pharmacol Toxicol, 45: 725-50. [Abstract] [Full-text]
135. The cardiac fibroblast: therapeutic target in myocardial remodeling and failure.
     Annu Rev Pharmacol Toxicol, 45: 657-87. [Abstract] [Full-text]
136. The magic bullets and tuberculosis drug targets.
     Annu Rev Pharmacol Toxicol, 45: 529-64. [Abstract] [Full-text]
137. Smart polyion complex micelles for targeted intracellular delivery of PEGylated antisense oligonucleotides containing acid-labile linkages.
     Chembiochem, 6(4): 718-25. [Abstract] [Full-text]
138. Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma.
     Cancer, 103(8): 1644-51. [Abstract] [Full-text]
139. The IVADo regimen--a pilot study with ifosfamide, vincristine, actinomycin D, and doxorubicin in children with metastatic soft tissue sarcoma: a pilot study of behalf of the European pediatric Soft tissue sarcoma Study Group.
     Cancer, 103(8): 1719-24. [Abstract] [Full-text]
140. Improving delivery of antineoplastic agents with anti-vascular endothelial growth factor therapy.
     Cancer, 103(8): 1561-70. [Abstract] [Full-text]
141. Procedural sedation and analgesia in the emergency department: what are the risks?
     Emerg Med Clin North Am, 23(2): 551-72. [Abstract] [Full-text]
142. Hormone replacement therapy and invasive and borderline epithelial ovarian cancer risk.
     Cancer Detect Prev, 29(2): 124-32. [Abstract] [Full-text]
143. Parelectric spectroscopy of drug-carrier-systems--distribution of carrier masses or activation energies.
     Biophys Chem, 114(2): 221-8. [Abstract] [Full-text]
144. Docetaxel and cyclooxygenase-2 inhibition with celecoxib for advanced non-small cell lung cancer progressing after platinum-based chemotherapy: a multicenter phase II trial.
     Lung Cancer, 48(2): 267-73. [Abstract] [Full-text]
145. Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).
     Lung Cancer, 48(2): 251-61. [Abstract] [Full-text]
146. Study of patients diagnosed with advanced HIV in the HAART era--OMEGA Cohort.
     Int J STD AIDS, 16(3): 252-5. [Abstract] [Full-text]
147. Initiation of highly active antiretroviral therapy in advanced AIDS with CD4 < 50 cells/mm3 in a resource-limited setting: efficacy and tolerability.
     Int J STD AIDS, 16(3): 243-6. [Abstract] [Full-text]
148. Prescribing patterns for antihypertensive drugs after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: report of experience in a health maintenance organization.
     Am J Hypertens, 18(4): 464-9. [Abstract] [Full-text]
149. Improved brain uptake and pharmacological activity profile of morphine-6-glucuronide using a peptide vector-mediated strategy.
     J Pharmacol Exp Ther, 313(2): 712-9. [Abstract] [Full-text]
150. Release of biologically functional interferon-alpha from a nanochannel delivery system.
     Biomed Microdevices, 7(1): 71-9. [Abstract] [Full-text]
151. Solid lipid nanoparticles as drug delivery systems.
     Methods Find Exp Clin Pharmacol, 27(2): 127-44. [Abstract] [Full-text]
152. Penetration of moxifloxacin into the human aqueous humour after oral administration.
     Br J Ophthalmol, 89(5): 628-31. [Abstract] [Full-text]
153. Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors.
     Cancer Res, 65(8): 3336-46. [Abstract] [Full-text]
154. Epidermal growth factor receptor dynamics influences response to epidermal growth factor receptor targeted agents.
     Cancer Res, 65(8): 3003-10. [Abstract] [Full-text]
155. Adjuvant chemotherapy of lung cancer: methodologic issues and therapeutic advances.
     Hematol Oncol Clin North Am, 19(2): 263-81, vi. [Abstract] [Full-text]
156. Comparison of laser beam intensity profiles produced by photodynamic therapy (PDT) and transpupillary thermotherapy (TTT) lasers.
     Lasers Surg Med, 36(4): 315-22. [Abstract] [Full-text]
157. Treatment of port wine stains with photodynamic therapy, using pulsed dye laser as a light source, compared with pulsed dye laser alone: a pilot study.
     Lasers Surg Med, 36(4): 266-9. [Abstract] [Full-text]
158. Investigations of calsequestrin as a target for anthracyclines: comparison of functional effects of daunorubicin, daunorubicinol, and trifluoperazine.
     Mol Pharmacol, 67(5): 1505-12. [Abstract] [Full-text]
159. Mechanisms involved in the low-level regeneration of CD4+ cells in HIV-1-infected patients receiving highly active antiretroviral therapy who have prolonged undetectable plasma viral loads.
     J Infect Dis, 191(10): 1670-9. [Abstract] [Full-text]
160. Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18.
     J Clin Oncol, 23(12): 2831-9. [Abstract] [Full-text]
161. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.
     J Clin Oncol, 23(12): 2822-30. [Abstract] [Full-text]
162. Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.
     J Clin Oncol, 23(12): 2694-702. [Abstract] [Full-text]
163. Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial.
     J Clin Oncol, 23(12): 2686-93. [Abstract] [Full-text]
164. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group.
     J Clin Oncol, 23(12): 2676-85. [Abstract] [Full-text]
165. Combined GADD45A and thymidine phosphorylase expression levels predict response and survival of neoadjuvant-treated gastric cancer patients.
     Clin Cancer Res, 11(8): 3025-31. [Abstract] [Full-text]
166. Synthesis and photochemotherapeutic activity of thiopyrano[2,3-e]indol-2-ones.
     Bioorg Med Chem Lett, 15(9): 2291-4. [Abstract] [Full-text]
167. Using light in dermatology: an update on lasers, ultraviolet phototherapy, and photodynamic therapy.
     Dermatol Clin, 23(2): 199-207. [Abstract] [Full-text]
168. The use of irinotecan and oxaliplatin in the treatment of advanced colorectal cancer.
     Eur J Surg Oncol, 31(4): 325-30. [Abstract] [Full-text]
169. Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the International Society of Paediatric Oncology--SIOP Malignant Mesenchymal Tumor 89.
     J Clin Oncol, 23(12): 2618-28. [Abstract] [Full-text]
170. Plasma sex hormone concentrations and subsequent risk of breast cancer among women using postmenopausal hormones.
     J Natl Cancer Inst, 97(8): 595-602. [Abstract] [Full-text]
171. Hormonal contraceptive use and the effectiveness of highly active antiretroviral therapy.
     Am J Epidemiol, 161(9): 881-90. [Abstract] [Full-text]
172. Photodynamic therapy with topical methyl aminolaevulinate for 'difficult-to-treat' basal cell carcinoma.
     Br J Dermatol, 152(4): 765-72. [Abstract] [Full-text]
173. Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancer.
     Int J Gynecol Cancer, 15: 36-41. [Abstract] [Full-text]
174. Management of platinum-sensitive relapsed ovarian cancer, with particular reference to the International Collaboration in Ovarian Neoplasm-4/Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer-2.2 trial.
     Int J Gynecol Cancer, 15: 31-5. [Abstract] [Full-text]
175. Review of gemcitabine-based combinations for platinum-resistant ovarian cancer.
     Int J Gynecol Cancer, 15: 23-30. [Abstract] [Full-text]
176. A phase I/II dose-escalation study of exisulind and docetaxel in patients with hormone-refractory prostate cancer.
     BJU Int, 95(7): 963-8. [Abstract] [Full-text]
177. Intensive graft-versus-host disease prophylaxis is required after unrelated-donor nonmyeloablative stem cell transplantation.
     Bone Marrow Transplant, 35(9): 921-6. [Abstract] [Full-text]
178. Prospective study of the effectiveness of percutaneous transhepatic photodynamic therapy for advanced bile duct cancer and the role of intraductal ultrasonography in response assessment.
     Endoscopy, 37(5): 425-33. [Abstract] [Full-text]
179. Poor results of 5-aminolevulinic acid-photodynamic therapy for residual high-grade dysplasia and early cancer in barrett esophagus after endoscopic resection.
     Endoscopy, 37(5): 418-24. [Abstract] [Full-text]
180. Neonatal effects of breast cancer chemotherapy administered during pregnancy.
     Pharmacotherapy, 25(3): 438-41. [Abstract] [Full-text]
181. Fatal amphotericin B overdose due to administration of nonlipid formulation instead of lipid formulation.
     Pharmacotherapy, 25(3): 426-8. [Abstract] [Full-text]
182. Antiangiogenic photodynamic therapy (PDT) by using long-circulating liposomes modified with peptide specific to angiogenic vessels.
     Biochim Biophys Acta, 1669(1): 69-74. [Abstract] [Full-text]
183. Synthesis and membrane behavior of a new class of unnatural phospholipid analogs useful as phospholipase A2 degradable liposomal drug carriers.
     Biochim Biophys Acta, 1669(1): 1-7. [Abstract] [Full-text]
184. One versus two high-dose cytarabine-based consolidation before autologous stem cell transplantation for young acute myeloblastic leukaemia patients in first complete remission.
     Br J Haematol, 129(3): 403-10. [Abstract] [Full-text]
185. Cutaneous effects of highly active antiretroviral therapy in HIV-infected patients.
     Dermatol Ther, 18(1): 58-66. [Abstract] [Full-text]
186. Pharmacokinetic interaction on valproic acid and recurrence of epileptic seizures during chemotherapy in an epileptic patient.
     Br J Clin Pharmacol, 59(5): 593-7. [Abstract] [Full-text]
187. Impact of hormone replacement therapy on microvascular function in healthy and Type 2 diabetic postmenopausal women.
     Diabet Med, 22(5): 536-42. [Abstract] [Full-text]
188. The effect of the phytoestrogen genistein and hormone replacement therapy on homocysteine and C-reactive protein level in postmenopausal women.
     Acta Obstet Gynecol Scand, 84(5): 474-7. [Abstract] [Full-text]
189. Clinical outcome after 4 years follow-up of HIV-seropositive subjects with incomplete virologic or immunologic response to HAART.
     J Med Virol, 76(2): 153-60. [Abstract] [Full-text]
190. Epidemiological and phylogenetic evidence for patient-to-patient hepatitis C virus transmission during sclerotherapy of varicose veins.
     J Med Virol, 76(2): 279-84. [Abstract] [Full-text]
191. High dose chemotherapy and autologous stem cell transplantation as adjuvant therapy for primary breast cancer patients with four or more lymph nodes involved: long-term results of an international randomised trial.
     Ann Oncol, 16(5): 726-34. [Abstract] [Full-text]
192. Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer: a phase I-II study.
     Ann Oncol, 16(5): 762-6. [Abstract] [Full-text]
193. Adjuvant treatment for elderly patients with stage III colon cancer in the southern Netherlands is affected by socioeconomic status, gender, and comorbidity.
     Ann Oncol, 16(5): 767-72. [Abstract] [Full-text]
194. Timing of CMF chemotherapy in combination with tamoxifen in postmenopausal women with breast cancer: role of endocrine responsiveness of the tumor.
     Ann Oncol, 16(5): 716-25. [Abstract] [Full-text]
195. Carboplatin plus gemcitabine in patients with inoperable or metastatic pancreatic cancer: a phase II multicenter study by the Hellenic Cooperative Oncology Group.
     Ann Oncol, 16(5): 773-9. [Abstract] [Full-text]
196. Worse survival for TP53 (p53)-mutated breast cancer patients receiving adjuvant CMF.
     Ann Oncol, 16(5): 743-8. [Abstract] [Full-text]
197. cTnT can be a useful marker for early detection of anthracycline cardiotoxicity.
     Ann Oncol, 16(5): 798-804. [Abstract] [Full-text]
198. Prevalence of fat redistribution and metabolic disorders in human immunodeficiency virus-infected children.
     Eur J Pediatr, 164(5): 271-6. [Abstract] [Full-text]
199. Hodgkin lymphoma therapy with interleukin-4 receptor-directed cytotoxin in an infiltrating animal model.
     Blood, 105(9): 3707-13. [Abstract] [Full-text]
200. Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222.
     Blood, 105(9): 3420-7. [Abstract] [Full-text]
201. Empiric antibiotic coverage of atypical pathogens for community acquired pneumonia in hospitalized adults.
     Cochrane Database Syst Rev. [Abstract] [Full-text]
202. Chemotherapy for advanced gastric cancer.
     Cochrane Database Syst Rev. [Abstract] [Full-text]
203. Single agent versus combination chemotherapy for metastatic breast cancer.
     Cochrane Database Syst Rev. [Abstract] [Full-text]
204. Hormone replacement therapy for preventing cardiovascular disease in post-menopausal women.
     Cochrane Database Syst Rev. [Abstract] [Full-text]
205. Therapeutic options for refractory massive pleural effusion in systemic lupus erythematosus: a case study and review of the literature.
     Semin Arthritis Rheum, 34(5): 744-9. [Abstract] [Full-text]
206. Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate- and non-methotrexate-containing graft-versus-host disease prophylaxis regimens.
     Biol Blood Marrow Transplant, 11(5): 383-8. [Abstract] [Full-text]
207. Exercise as an alternative to oral estrogen for amelioration of endothelial dysfunction in postmenopausal women.
     Am Heart J, 149(2): 291-7. [Abstract] [Full-text]
208. Invasive versus noninvasive management of ST-elevation acute myocardial infarction: a review of clinical trials and observational studies.
     Am Heart J, 149(2): 194-9. [Abstract] [Full-text]
209. No increase in rates of early-onset neonatal sepsis by antibiotic-resistant group B Streptococcus in the era of intrapartum antibiotic prophylaxis.
     Am J Obstet Gynecol, 192(4): 1167-71. [Abstract] [Full-text]
210. Beyond the pill: new data and options in hormonal and intrauterine contraception.
     Am J Obstet Gynecol, 192(4): 998-1004. [Abstract] [Full-text]
211. Postmenopausal hormone therapy: from monkey glands to transdermal patches.
     J Endocrinol, 185(2): 207-22. [Abstract] [Full-text]
212. Preoperative gabapentin decreases anxiety and improves early functional recovery from knee surgery.
     Anesth Analg, 100(5): 1394-9, table of contents. [Abstract] [Full-text]
213. Phase II study of irinotecan, 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer.
     Jpn J Clin Oncol, 35(4): 214-7. [Abstract] [Full-text]
214. Phase II study of carboplatin-paclitaxel combination chemotherapy in elderly patients with advanced non-small cell lung cancer.
     Jpn J Clin Oncol, 35(4): 188-94. [Abstract] [Full-text]
215. A phase I/II study comparing regimen schedules of gemcitabine and docetaxel in Japanese patients with stage IIIB/IV non-small cell lung cancer.
     Jpn J Clin Oncol, 35(4): 181-7. [Abstract] [Full-text]
216. Efficient Ex vivo stimulation of Mycobacterium tuberculosis-specific T cells by genetically detoxified Bordetella pertussis adenylate cyclase antigen toxoids.
     Infect Immun, 73(5): 2991-8. [Abstract] [Full-text]
217. Intra-arterial thrombolysis in acute ischaemic stroke.
     Intern Med J, 35(5): 300-2. [Abstract] [Full-text]
218. Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer.
     Br J Cancer, 92(8): 1372-81. [Abstract] [Full-text]
219. Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma.
     Br J Cancer, 92(8): 1352-7. [Abstract] [Full-text]
220. The development and characterisation of porphyrin isothiocyanate-monoclonal antibody conjugates for photoimmunotherapy.
     Br J Cancer, 92(8): 1442-9. [Abstract] [Full-text]
221. Distinct transduction mechanisms of cyclooxygenase 2 gene activation in tumour cells after photodynamic therapy.
     Oncogene, 24(18): 2981-91. [Abstract] [Full-text]
222. Polymeric micelles for delivery of poorly soluble drugs: preparation and anticancer activity in vitro of paclitaxel incorporated into mixed micelles based on poly(ethylene glycol)-lipid conjugate and positively charged lipids.
     J Drug Target, 13(1): 73-80. [Abstract] [Full-text]
223. In vivo evidence for the efflux transport of pentazocine from the brain across the blood-brain barrier using the brain efflux index method.
     J Drug Target, 13(1): 53-9. [Abstract] [Full-text]
224. Hormone replacement therapy, reproductive factors, and age-related macular degeneration: the Salisbury Eye Evaluation Project.
     Ophthalmic Epidemiol, 12(1): 37-45. [Abstract] [Full-text]
225. Design of a phytosphingosine-containing, positively-charged nanoemulsion as a colloidal carrier system for dermal application of ceramides.
     Eur J Pharm Biopharm, 60(1): 91-8. [Abstract] [Full-text]
226. Pharmacokinetics of an immediate release, a controlled release and a two pulse dosage form in dogs.
     Eur J Pharm Biopharm, 60(1): 17-23. [Abstract] [Full-text]
227. Cationic albumin conjugated pegylated nanoparticle with its transcytosis ability and little toxicity against blood-brain barrier.
     Int J Pharm, 295(1): 247-60. [Abstract] [Full-text]
228. Chitosan nanoparticles as a novel delivery system for ammonium glycyrrhizinate.
     Int J Pharm, 295(1): 235-45. [Abstract] [Full-text]
229. Glycodendrimeric nanoparticulate carriers of primaquine phosphate for liver targeting.
     Int J Pharm, 295(1): 221-33. [Abstract] [Full-text]
230. Controlled delivery of testosterone from smart polymer solution based systems: in vitro evaluation.
     Int J Pharm, 295(1): 183-90. [Abstract] [Full-text]
231. In vivo behaviour of vesicular urokinase.
     Int J Pharm, 295(1): 1-6. [Abstract] [Full-text]
232. Adjuvant chemotherapy in the treatment of high grade gliomas.
     Cancer Treat Rev, 31(2): 79-89. [Abstract] [Full-text]
233. Where there is no state: household strategies for the management of illness in Chad.
     Soc Sci Med, 61(1): 229-43. [Abstract] [Full-text]
234. Resisting medicines: a synthesis of qualitative studies of medicine taking.
     Soc Sci Med, 61(1): 133-55. [Abstract] [Full-text]
235. Therapeutic management of brain metastasis.
     Lancet Neurol, 4(5): 289-98. [Abstract] [Full-text]
236. Gene delivery through cell culture substrate adsorbed DNA complexes.
     Biotechnol Bioeng, 90(3): 290-302. [Abstract] [Full-text]
237. Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib.
     Cancer, 103(9): 1850-5. [Abstract] [Full-text]
238. Chemosensitization by STI571 targeting the platelet-derived growth factor/platelet-derived growth factor receptor-signaling pathway in the tumor progression and angiogenesis of gastric carcinoma.
     Cancer, 103(9): 1800-9. [Abstract] [Full-text]
239. Phase I dose-escalation study of tezacitabine in combination with 5-fluorouracil in patients with advanced solid tumors.
     Cancer, 103(9): 1925-31. [Abstract] [Full-text]
240. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy.
     Cancer, 103(9): 1916-24. [Abstract] [Full-text]
241. Lower doses of oral estrogen and progestogens as treatment for postmenopausal women.
     Semin Reprod Med, 23(2): 188-95. [Abstract] [Full-text]
242. Female sexual dysfunction and use of hormone therapy in postmenopausal women.
     Semin Reprod Med, 23(2): 180-7. [Abstract] [Full-text]
243. Breast cancer: the role of hormone therapy.
     Semin Reprod Med, 23(2): 167-71. [Abstract] [Full-text]
244. The applicability of hormonal effects on atherosclerosis in animals to heart disease in postmenopausal women.
     Semin Reprod Med, 23(2): 149-56. [Abstract] [Full-text]
245. Vaginal hormone therapy for urogenital and menopausal symptoms.
     Semin Reprod Med, 23(2): 126-40. [Abstract] [Full-text]
246. Reducing excessive medication administration in hospitalized adults with renal dysfunction.
     Am J Med Qual, 20(2): 64-9. [Abstract] [Full-text]
247. Chronomodulation of topotecan or X-radiation treatment increases treatment efficacy without enhancing acute toxicity.
     Int J Radiat Oncol Biol Phys, 62(1): 230-7. [Abstract] [Full-text]
248. Consolidative abdominopelvic radiotherapy after surgery and carboplatin/paclitaxel chemotherapy for epithelial ovarian cancer.
     Int J Radiat Oncol Biol Phys, 62(1): 104-10. [Abstract] [Full-text]
249. Clinical experience with chronomodulated infusional 5-fluorouracil chemoradiotherapy for pancreatic adenocarcinoma.
     Int J Radiat Oncol Biol Phys, 62(1): 97-103. [Abstract] [Full-text]
250. Phase I trial of oxaliplatin in combination with cisplatin, protacted-infusion fluorouracil, and radiotherapy in advanced esophageal and gastroesophageal carcinoma.
     Int J Radiat Oncol Biol Phys, 62(1): 91-6. [Abstract] [Full-text]
251. Phase II study of radiotherapy with three-dimensional conformal boost concurrent with paclitaxel and cisplatin for Stage IIIB non-small-cell lung cancer.
     Int J Radiat Oncol Biol Phys, 62(1): 76-81. [Abstract] [Full-text]
252. Quality of life in patients with age-related macular degeneration: impact of the condition and benefits of treatment.
     Surv Ophthalmol, 50(3): 263-73. [Abstract] [Full-text]
253. Increased BNip3 and decreased mutant p53 in cisplatin-sensitive PDT-resistant HT29 cells.
     Biochem Biophys Res Commun, 331(2): 648-57. [Abstract] [Full-text]
254. In vivo EPR spectroscopic imaging for a liposomal drug delivery system.
     Magn Reson Med, 53(5): 1158-65. [Abstract] [Full-text]
255. Value of intravenous 6-mercaptopurine during continuation treatment in childhood acute lymphoblastic leukemia and non-Hodgkin's lymphoma: final results of a randomized phase III trial (58881) of the EORTC CLG.
     Leukemia, 19(5): 721-6. [Abstract] [Full-text]
256. Sequence effect of docetaxel and carboplatin on toxicity, tumor response and pharmacokinetics in non-small-cell lung cancer patients: a phase I study of two sequences.
     Cancer Chemother Pharmacol, 55(6): 552-8. [Abstract] [Full-text]
257. Mechanical and antibacterial bowel preparation in colon and rectal surgery.
     Chemotherapy, 51: 115-21. [Abstract] [Full-text]
258. Mechanistic study of the photodynamic inactivation of Candida albicans by a cationic porphyrin.
     Antimicrob Agents Chemother, 49(5): 2026-34. [Abstract] [Full-text]
259. Influence of patients' requests for direct-to-consumer advertised antidepressants: a randomized controlled trial.
     JAMA, 293(16): 1995-2002. [Abstract] [Full-text]
260. Characterization of the rotating dialysis cell as an in vitro model potentially useful for simulation of the pharmacokinetic fate of intra-articularly administered drugs.
     Eur J Pharm Sci, 25(1): 73-9. [Abstract] [Full-text]
261. Astrocytic swelling in cerebral ischemia as a possible cause of injury and target for therapy.
     Glia, 50(4): 389-97. [Abstract] [Full-text]
262. A phase IB study of the pharmacokinetics of gemcitabine and pemetrexed, when administered in rapid sequence to patients with advanced solid tumors.
     Cancer Chemother Pharmacol, 55(6): 522-30. [Abstract] [Full-text]
263. A pharmacological study of celecoxib and gemcitabine in patients with advanced pancreatic cancer.
     Cancer Chemother Pharmacol, 55(6): 559-64. [Abstract] [Full-text]
264. Improvement of paclitaxel therapeutic index by derivatization and association to a cholesterol-rich microemulsion: in vitro and in vivo studies.
     Cancer Chemother Pharmacol, 55(6): 565-76. [Abstract] [Full-text]
265. 5-Fluorouracil/irinotecan induced lethal toxicity as a result of a combined pharmacogenetic syndrome: report of a case.
     J Clin Pathol, 58(5): 553-5. [Abstract] [Full-text]
266. Early signs of brain infarction at CT: observer reliability and outcome after thrombolytic treatment--systematic review.
     Radiology, 235(2): 444-53. [Abstract] [Full-text]
267. The physical, emotional and interpersonal impact of HAART: exploring the realities of HIV seropositive individuals on combination therapy.
     J Health Psychol, 10(3): 345-58. [Abstract] [Full-text]
268. Acustimulation wrist bands are not effective for the control of chemotherapy-induced nausea in women with breast cancer.
     J Pain Symptom Manage, 29(4): 376-84. [Abstract] [Full-text]
269. Palliation of bone pain in prostate cancer using chemotherapy and strontium-89. A randomized phase II study.
     J Pain Symptom Manage, 29(4): 352-7. [Abstract] [Full-text]
270. Use of opioids in a Danish population-based cohort of cancer patients.
     J Pain Symptom Manage, 29(4): 336-43. [Abstract] [Full-text]
271. Porphyrin-related photosensitizers for cancer imaging and therapeutic applications.
     J Microsc, 218: 133-47. [Abstract] [Full-text]
272. Effects of including soy protein in a blood cholesterol-lowering diet on markers of cardiac risk in men and in postmenopausal women with and without hormone replacement therapy.
     J Womens Health (Larchmt), 14(3): 253-62. [Abstract] [Full-text]
273. Memory of insulin pumps and their record as a source of information about insulin therapy in children and adolescents with type 1 diabetes.
     Diabetes Technol Ther, 7(2): 308-14. [Abstract] [Full-text]
274. Optimal insulin pump dosing and postprandial glycemia following a pizza meal using the continuous glucose monitoring system.
     Diabetes Technol Ther, 7(2): 233-40. [Abstract] [Full-text]
275. Strategies for initiating combination antiretroviral therapy.
     AIDS Patient Care STDS, 19(4): 224-38. [Abstract] [Full-text]
276. Increase in body cell mass and decrease in wasting are associated with increasing potency of antiretroviral therapy for HIV infection.
     AIDS Patient Care STDS, 19(4): 216-23. [Abstract] [Full-text]
277. A TAT-streptavidin fusion protein directs uptake of biotinylated cargo into mammalian cells.
     Protein Eng Des Sel, 18(3): 147-52. [Abstract] [Full-text]
278. Structured conversion from thrice weekly to weekly erythropoietic regimens using a computerized decision-support system: a randomized clinical study.
     J Am Soc Nephrol, 16(5): 1463-70. [Abstract] [Full-text]
279. Nanoporous delivery system to treat osteomyelitis and regenerate bone: gentamicin release kinetics and bactericidal effect.
     J Biomed Mater Res B Appl Biomater, 73(2): 277-84. [Abstract] [Full-text]
280. Treatment of advanced non-small-cell lung cancer in the elderly: results of an international expert panel.
     J Clin Oncol, 23(13): 3125-37. [Abstract] [Full-text]
281. Side effects and cancer-related stress determine quality of life in long-term survivors of testicular cancer.
     J Clin Oncol, 23(13): 3061-8. [Abstract] [Full-text]
282. C